NCT04133792View on ClinicalTrials.gov

Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

571

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2030

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Simvastatin 40mg

40 mg orally daily for 5 years.

DRUG

Placebo oral tablet

40 mg orally daily for 5 years.

Trial Locations (12)

41685

Sahlgrenska Universitetssjukhuset Östra, Gothenburg

222 42

Skåne Universitetssjukhus, Malmo

907 37

Norrlands Universitetssjukhus, Umeå

413 45

Sahlgrenska Universitetssjukhuset, Gothenburg

652 30

Karlstads centralsjukhus, Karlstad

Unknown

Skaraborgs sjukhus, Lidköping

701 85

Örebro Universitetssjukhus, Örebro

141 57

Karolinska University Hospital, Stockholm

171 64

Karolinska University Hospital Solna, Stockholm

182 57

Danderyds sjukhus, Stockholm

751 85

Akademiska sjukhuset, Uppsala

581 85

Universitetssjukhuset i Linköping, Linköping

All Listed Sponsors
lead

Annika Bergquist

OTHER